| abstract |
These compounds are useful in the treatment or prevention of a condition or disorder associated with the activity of DGAT1 in animals, in particular in humans, such as inflammatory conditions, obesity, diabetes and related metabolic disorders. Claim 1: A crystalline form of the sodium salt of the (4- {4- [5- (6-trifluoro-methyl-pyridin-3-yl-amino) -pyridin-2-yl] -phenyl) -cyclohexyl) -acetic acid of the formula (1) in the form of Modification B, C, D, F, I, L, N, or O. |